

Research Article

The Expression of *ARMCX1* in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy

Changheng Lv ^{1,2}, Di Yang,^{1,2} Donghu Zhang ², Jiajia Shen,¹ Zechen Wang ¹,
Siyan He,¹ Lingzhang Meng ^{1,3}, Jian Song ^{1,3} and Jingjie Zhao ⁴

¹Center for Systemic Inflammation Research (CSIR), School of Preclinical Medicine, Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

²Department of Pediatric Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

³Institute of Cardiovascular Sciences, Guangxi Academy of Medical Sciences, Nanning, Guangxi Province, China

⁴Life Science and Clinical Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

Correspondence should be addressed to Lingzhang Meng; lingzhang.meng@ymun.edu.cn, Jian Song; songj@uni-muenster.de, and Jingjie Zhao; jingjie.zhao@ymun.edu.cn

Received 9 June 2022; Accepted 26 October 2022; Published 23 January 2023

Academic Editor: Payam Behzadi

Copyright © 2023 Changheng Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The altered expression of *ARMCX1* in patients with gastric cancer has been reported frequently, yet its correlation to prognosis and chemotherapy needs to be unveiled. In combination of the gene expression data retrieved from TCGA database and bioinformatic analysis, this study discovered 590 differentially expressed genes in the cancerous biopsies isolated from gastric patients, compared with controls. Among which, *ARMCX1* exhibited great potential to serve as a prognostic biomarker for gastric patients; furthermore, patients with low expression of *ARMCX1* could be more sensitive to these 9 chemotherapeutic agents: A-770041, AMG-706, ATRA, BEZ235, bortezomib, CGP60474, dasatinib, HG-64-1, and pazopanib, rather than the other chemotherapeutic agents. This study helps the improvement of evaluating the prognosis of gastric cancer patients, and would help optimize chemotherapeutic strategies in consideration of the expression of *ARMCX1*.

1. Introduction

Gastric cancer (GC), or stomach cancer, was listed among the top common cancers throughout the whole world [1–3] and ranks sixth in cancer incidence but second in mortality [4]. The World Health Organization estimated over one million new patients and 769,000 death reports from GC only in 2020, with the highest incidence rates in Asian countries such as Japan, Mongolia, and China [5]. The various treatment options for GC include surgery, radiotherapy, chemotherapy, gene therapy, immunotherapy, and multidisciplinary therapeutic strategy, though help improve the therapeutic outcomes as reported [6], GC remains a major cause of cancer mortality worldwide, with

above 700,000 deaths annually [7]. Thus, it is vital to determine the molecular mechanisms that lead to GC, to improve the therapeutic effect.

The gene “ARM Protein Lost In Epithelial Cancers On Chromosome X 1 (*ARMCX1*)”, also represented as *ALEX1*, locating at chromosome region Xq21.33-q22.2, contributes to tumorigenesis [8]. *ARMCX1* has a role in regulation of mitochondrial transport especially in the process of neuronal repair [9]. Recent studies have shown that *ARMCX1* is down-regulated in epithelial cancer [10]. Its protein could significantly inhibit the occurrence of GC via affecting the PAR-1/Rho GTPase pathway [11]. Thus, researchers have found *ARMCX1* to be a biomarker to predict the prognosis of GC, and this protein could serve to increase the therapeutic effects.

Therefore, this study is aimed at comprehensively delineating the expression profile of *ARMCX1* in GC patients, to clarify its associations with clinical data and patient prognosis, as well as the potential mechanisms by which *ARMCX1* affects GC progression. Overall, this study identified the relationship between *ARMCX1* and its role in regulating the microenvironment in GC, and evaluated its role in affecting chemotherapy.

2. Materials and Methods

2.1. GC Data Collection. The expression of *ARMCX1* in various cancer patients was analyzed with TIMER, an internet-based tool for comprehensive analysis of immune phenotypes [12, 13]. The GDC data portal was used to download the FPKM gene expression matrix of GC patients in the TCGA database. The TCGA GC cohort dataset consisted of 435 GC patients and 35 normal tissues. All clinical data and demographic information were checked and filtered from the TCGA portal using the UCSC Cruz Xena functional genomics explorer.

2.2. Differences in *ARMCX1* mRNA and Protein Expression between GC and Normal Biopsies. *ARMCX1* mRNA expression in GC was analyzed with limma package in the R Software (version 4.1.2) [14], and with R packages, ggplot2 and pheatmap. The HPA database was employed to validate *ARMCX1* protein expression levels in GC through immunohistochemistry [15, 16].

2.3. Flow Cytometry Analysis. Gastric cancerous tissues were isolated from patients by surgery, the paracarcinoma tissues were used as controls in this study. The freshly isolated tissues were digested with Collagenase IV (Gibco, #17104) according to manufacturer's protocols. After resuspension with PBS containing 0.5% BSA, the cells were blocked for unspecific bindings, then the cells were incubated with FITC *ARMCX1* (Biorbyt, #orb102105) on ice for 15 minutes. After washing twice, the cells were recorded on a ThermalFisher Attune Nxt machine. The debris were removed by counterstaining with propidium iodide.

2.4. Correlation between *ARMCX1* Expression and Clinical Information. Based on the mean values, patients with GC were grouped into low group with low expression of *ARMCX1*, and another group with high expression. The clinical data including pathological patterns, clinical stage, and information from follow-up study of GC patients, were assessed, and the association between *ARMCX1* and the clinical pathological data was analyzed.

2.5. Survival Analysis of *ARMCX1* in GC. Overall survival (OS), together with progression-free survival (PFS) were calculated with the Kaplan–Meier (KM) method. Univariate and multivariate methods were used to perform prognosis analysis.

2.6. Identification of DEGs, GSEA Analysis. Patients/clinical data were stratified into two groups based on the *ARMCX1* expression. DEGs were calculated between the high and

low *ARMCX1* expression level. A p value lower than 0.05 and $|\log_{2}FC|$ value higher or equal to 1 were taken as significant statistically. In addition, the R packages “clusterProfiler,” “http://org.Hs.eg.db,” “enrichplot,” and “ggplot2” were used to conduct GO and KEGG enrichment analyses on the DEGs. GSEA was employed to evaluate the pathways and molecular mechanisms involved in the development of GC [17].

2.7. Analysis of the Correlation between *ARMCX1* Expression and the Immune Microenvironment of GC. We used the ESTIMATE algorithm to acquire immune score and stromal score in tumor microenvironment of GC patients, revealing the correlation with *ARMCX1* expression. In addition, we utilized the CIBERSORT method to investigate immune cell infiltration features in GC. The tumor mutation burden (TMB) within a particular region was used for correlation test by Spearman's rank analysis.

2.8. Sensitivity Analysis of Chemotherapeutic Agents. The R package pRRophetic was used to explore the sensitivity of chemotherapeutic agents. In the present study, the IC50 values of the most common chemotherapy drugs were calculated using the R packages pRRophetic and ggplot2 to assess clinical responses to treatment.

2.9. Statistical Analysis. The χ^2 test was used to compare the clinical parameters between the groups classified by the high and low expression of *ARMCX1*. Survival analysis was performed using the KM method. For determining the independent prognostic factors, we performed both univariate and multivariate analyses. The Spearman method was applied for correlation analysis. For all analyses, p value lower than 0.05 was taken as significant. In all the figures shown in this study, the asterisks indicate statistically significant differences (* refers $p < 0.05$; ** refers $p < 0.01$, and *** refers $p < 0.001$).

3. Results

The analysis with TIMER showed that *ARMCX1* was drastically lower in various cancerous tissues, such as malignant bladder, breast, uterine neck, colon, kidney, lung, prostates, stomach, and thyroid; while *ARMCX1* expression was higher in cholangiocarcinoma (Figure 1(a)). Besides, we noticed from the TCGA cohort dataset that the gene *ARMCX1* was drastically lower in GC than in normal tissues (Figures 1(b) and 1(c)). Furthermore, the HPA portal showed that *ARMCX1* protein was lower in GC than in controls, especially when compared to that in adipose tissue (Figures 1(d) and 1(e)). In consistence, flow cytometry analysis of gastric cancerous biopsies showed *ARMCX1* is significantly lower than in paracarcinoma controls (Figures 1(f) and 1(g)).

Correlation test between two groups (one group contained GC patients with high expression of *ARMCX1*, another contained low expression) exhibited that *ARMCX1* expression was correlated with age, Grade, and T; however no significant correlation with sex, stage, M, and N (Figure 1(h)).




FIGURE 1: GC biopsies exhibited lower expression of *ARM CX1*. (a) *ARM CX1* expression in various cancerous tissues. (b, c) *ARM CX1* expression in The Cancer Genome Atlas database compared with that in normal tissue. (d, e) Immunohistochemistry staining showed *ARM CX1* protein in GC tissue. (f) Contour plots showed the expression of *ARM CX1* in gastric cancer biopsies compared with paracarcinoma controls. (g) Statistical analysis of the expression level of *ARM CX1* in gastric cancer biopsies compared with paracarcinoma controls. ** $p < 0.01$. Each dot represents one readout. Nonparametric test. (h) Correlation between *ARM CX1* and clinicopathological data of patients with GC.

KM analysis showed individuals with high *ARM CX1* expression could have a worse OS ($p = 0.008$), while patients with low *ARM CX1* expression had nice FDS value ($p = 0.027$) (Figures 2(a) and 2(b)). Univariate analysis indicated that *ARM CX1* expression ($p = 0.003$), age ($p < 0.001$), and stage ($p < 0.001$) were prognostic factors (Figure 2(c)). Furthermore, *ARM CX1* showed a great potential to predict the survival of GC patients, based on multivariate analysis ($p < 0.011$) (Figure 2(d)). Such an outcome indicates *ARM CX1* could serve as an independent biomarker for prognosis.

Based on which, we built a nomogram that could be used for the prediction of 1-year, or 3-year, and or 5-year OS for GC patients (Figure 2(e)).

Depending on the median expression of *ARM CX1*, patients were classified as having either high or low *ARM CX1* levels. 590 DEGs were identified between these two groups (Figure 3(a)). Additionally, we performed a KEGG pathway analysis, and the results are shown as a bubble chart (Figure 3(b)). A circular chart depicts GO analysis of DEGs (Figure 3(c)). GSEA revealed that 22 KEGG pathway-related gene sets were enriched, and a sample GSEA enrichment plot is shown (Figure 3(d)).

Furthermore, we compared the stromal, immune, and ESTIMATE scores between low-/high-*ARM CX1* expression groups. It showed that high *ARM CX1* expression showed significantly higher immune, stromal, and ESTIMATE scores (Figure 4(a)). Naïve B cells, resting CD4 memory T cells, monocytes, M2 macrophages, and resting mast cells exhibited higher expression, while activated CD4 memory T cells, follicular helper T cells, resting NK cells, M1 macrophages, and neutrophils were expressed at lower levels in the high *ARM CX1* group than in the low *ARM CX1* expression group (Figure 4(b)). Correlation analysis revealed that *ARM CX1* expression was significantly positively associated

with monocytes, resting mast cells, resting CD4 memory T cells, resting dendritic cells, naïve B cells, M2 macrophages, regulatory T cells (Tregs), and activated NK cells. Additionally, M1 macrophages, activated mast cells, M0 macrophages, follicular helper T cells, neutrophils, activated CD4 memory T cells, and resting NK cells were negatively correlated with *ARM CX1* expression (Figure 4(c)). Next, we analyzed the correlation between *ARM CX1* and multiple immune checkpoints, which is illustrated in Figure 4(d). Finally, we calculated the TMB for each GC tumor sample. *ARM CX1* expression was negatively correlated with TMB in GC patients ($p < 2.2e - 16$, $R = -0.43$) (Figure 4(e)).

To better understand the differences in drug sensitivity between high and low-*ARM CX1* groups, we performed a GDSC drug sensitivity analysis using 61 different chemotherapeutic agents and found differences in drug sensitivity between these two groups. The top nine results showed that A-770041 ($p = 3.8e - 07$), AMG-706 ($p = 0.00032$), ATRA ($p = 5e - 06$), BEZ235 ($p = 6e - 11$), bortezomib ($p = 0.00019$), CGP-60474 ($p = 3.7e - 11$), dasatinib ($p = 5.6e - 09$), HG-64-1 ($p = 1e - 06$), and pazopanib ($p = 2.5e - 08$) exhibited better sensitivity in the low *ARM CX1* expression group (Figure 5).

4. Discussion

Using a pancancer analysis of TIMER databases, we examined the relationship between *ARM CX1* and multiple cancer tumorigenesis models. We also determined the clinical significance of *ARM CX1* in GC progression using the TCGA database. Both results showed that *ARM CX1* levels were lower in GC than in normal tissue. Using the HPA database, *Armcx1* protein was also lower in GC tissue compared to that in normal tissue. Clinical data showed that low







FIGURE 2: *ARM CX1* expression could potentially serve as a prognostic marker. (a) Correlation between *ARM CX1* expression and overall survival (OS). (b) Correlation between *ARM CX1* expression and PFS. (c) Multivariate analysis of overall survival. (d) Univariate analysis of overall survival. (e) The total nomogram point of each patient can be used to predict the probability of survival at 1, 3, and 5 years.



(a)



(b)



(c)

FIGURE 3: Continued.




FIGURE 3: Pathway analysis between high and low expression of *ARMCX1* in GC patients. (a) Heat maps of the DEGs between the high and low *ARMCX1* expression groups. (b) Bubble diagram of Kyoto Encyclopedia of Genes and Genomes mechanism analysis. (c) GO analysis of the DEGs between the high and low *ARMCX1* expression groups. (d) Significant pathways identified by GSEA analysis.

ARMCX1 was correlated with OS and PFS and serves as a “solo” prognostic factor. *ARMCX1* has been reported in various human tissues, including lung cancer, prostate cancer, colon cancer, pancreatic cancer, and ovarian cancer [18].

The function of *ARMCX1* is relatively unknown; however, a recent study reported that *ARMCX1* has been linked to the RNA damage response and RNA modification [19]. Similar to our results, Wang et al. revealed that the expression rate of *ARMCX1* was significantly reduced in GC samples compared to that in normal samples [20]. Some studies, however, have yielded conflicting results. Ecker et al. found that in cervical squamous cell carcinoma, the expression of *ARMCX1* protein was significantly increased compared with that in noncancerous tissues [21].

It has been observed that different outcomes from patients receiving chemotherapy, even those patients with the same cancer, for example, GC, but less is known about the molecular mechanism. This paper discovered *ARMCX1* could not only serve as a prognostic marker, but also potentially contribute to chemotherapy by affecting various signals, including regulation of mitochondrial dynamics. To clarify the mechanism by which *ARMCX1* contributes to GC progression, GO annotation, KEGG signaling pathway, and GSEA analyses were performed for the high and low *ARMCX1* expression groups. Here, we found that some classical signaling pathways may play important roles in GC, including the PI3K–Akt, cAMP, calcium, and cGMP–PKG signaling. The PI3K–AKT pathway, an important effector downstream of growth factor receptors, is dysregulated in cancer types [22–25]. It has been proven that PI3K/AKT/mTOR signaling regulates apoptosis and autophagy and constitute a molecular target for cancer therapy [26]. The PI3K/AKT/mTOR signaling pathway is

responsible for inhibiting autophagy in human cervical cancer cells by miR-338-3p [27]. Further, RA-induced apoptosis in breast cancer cells is mediated by the PI3K/AKT/mTOR pathway [28]. All of which participated in regulation of mitochondrial stability and dynamics [29–32]. Besides, GC has been associated with abnormal activating RAS initiated signaling [33, 34]. According to previous studies, ASPN also accelerates cell proliferation via PSMD2 and ELK, p38/MAPK, and PI3K/AKT signaling in GC cells [35–37]. But, whether *ARMCX1* could affect these signals needs to be further studied.

In this study, we discovered the expression level of *ARMCX1* in gastric cancer influences the outcome of chemotherapy (a clinical treatment initiated to destroy cancer cells), probably due to *ARMCX1*'s regulation on mitochondrial dynamics [38, 39], an important downstream procedure for the induction of cancer cell apoptosis [40, 41].

Moreover, it has been showed that cAMP signaling pathway is vital for the development of bladder cancer metastasis via affecting microtubule [42]. Long noncoding RNA KCNQ1OT1 upregulates the methotrexate resistance of colorectal cancer cells by inhibiting miR-760/PPP1R1B [43]. Elevated epinephrine levels in prostate cancer can inhibit apoptosis and drive tumor growth through the cAMP in murine [44]. The calcium signaling pathway plays an important role in breast cancer development [45]; moreover, calcium signaling is relevant to the proliferation, migration, invasion, and drug resistance of cancer cells [46–48].

The cGMP-PKG signaling pathway has also been linked to colon cancer and proposed as a therapeutic strategy for colon cancer [49]. Cell proliferation and apoptosis are critically affected by the cGMP-PKG pathway, which prevents colon cancer progression [32, 50, 51]. cGMP-PKG plays a




FIGURE 4: Comparison of tumor microenvironments between GC patients with high and low *ARMCX1* expression. (a) Difference in tumor microenvironment score between the high and low *ARMCX1* groups. (b) Immune infiltration by 22 immune cell types in patients with GC exhibiting high and low *ARMCX1* expression. (c) Correlation between *ARMCX1* gene expression and immune cell infiltration. (d) Correlations between *ARMCX1* expression with immune checkpoint gene expression. Red and green represent positive and negative correlations, respectively. (e) Correlations between *ARMCX1* gene and tumor mutation burden ($p < 2.2e-16$, $R = -0.43$).




FIGURE 5: Influence of *ARMCX1* on chemotherapy against GC. *ARMCX1* influenced chemotherapy induced by different drugs in GC patients.

central role in fibrotic processes in the liver, and defects in this pathway cause impaired NO-dependent responses in hepatic stellate cells on activation [52]. Burn-induced cardiac mitochondrial dysfunction is modulated via the cGMP-PKG pathway [53]. Overall, pathway network analysis showed that these signaling pathways may play key roles in GC progression.

Over the past decade, the TME has been intensely investigated, especially the immune microenvironment. We calculated TME scores based on the ESTIMATE algorithm to detect the correlations between immune/stromal/ESTIMATE scores and *ARMCX1* expression. We found that the high *ARMCX1* expression group displayed higher stromal scores, immune scores, and estimate scores than the low *ARMCX1* expression group. Similar to the present study,

bioinformatics analysis demonstrated that TOX expression is negatively correlated with TumorPurity and positively correlated with ImmuneScore and StromalScore in colorectal cancer [50]. Tumor-infiltrating immune cells are a part of the complex TME, which plays an essential role in tumor progression. Solid cancers are prone to infiltration by immune cells that contribute to tumor progression [51–53].

In this current study, five tumor-infiltrating immune cell types were more prevalent in the high *ARMCX1* expression group, while five other tumor-infiltrating immune cells (Naïve B cells, resting CD4 memory T cells, monocytes, M2 macrophages, and resting mast cells), which were prevalent in the low *ARMCX1* expression group. Among those tumor infiltrating immune cells, memory T cells, monocytes, and M2 macrophages have been extensively

studied, however, in this study, the biological/pathological role of the Naïve B cells and resting mast cells in the development of GC, needs to be elucidated.

Correlation analysis revealed that *ARMCX1* expression was significantly positively associated with eight tumor-infiltrating immune cell types, while six other tumor-infiltrating immune cells were negatively correlated with *ARMCX1* expression. Finally, we revealed that *ARMCX1* expression was correlated with immune checkpoints and TMB. Based on the results of this study, the correlations between *ARMCX1* expression and TME score, tumor infiltrating immune cells, immune checkpoints, and TMB may be useful to the development of novel cancer therapies.

Further studies should be performed including the adaptation of *ARMCX1* knockout mouse with GC symptoms to confirm the potential molecular mechanisms proposed by this study, by which, *ARMCX1* affects the prognostic procedure and chemotherapy.

5. Conclusion

According to our findings, variations in *ARMCX1* expression levels are associated with GC prognosis. In addition, this study indicated *ARMCX1* was associated obviously with multiple immune signatures. Therefore, the present study provides insights into the protective role of *ARMCX1* in tumor immunology and its potential as a prognostic biomarker for GC.

Data Availability

The datasets and code generated or analyzed in this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Authors' Contributions

Lingzhang Meng, Jingjie Zhao, and Jian Song designed this study. Chang Lv and Di Yang performed data analysis for this study. Donghu Zhang and Jiajia Shen organized the data and graphs for this study. Zechen Wang and Siyuan He helped perform flow cytometry analysis. Changheng Lv, Di Yang, and Donghu Zhang contributed equally to this study. Changheng Lv, Di Yang, and Donghu Zhang, these authors contributed equally to this work.

Acknowledgments

This research was funded by a grant from Youjiang Medical University for Nationalities Research Project (#yy2019bsky001).

References

- [1] D. M. Parkin, F. I. Bray, and S. S. Devesa, "Cancer burden in the year 2000. The global picture," *European Journal of Cancer*, vol. 37, Suppl 8, pp. S4–66, 2001.
- [2] D. M. Parkin, "International variation," *Oncogene*, vol. 23, no. 38, pp. 6329–6340, 2004.
- [3] J. Ferlay, I. Soerjomataram, R. Dikshit et al., "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012," *International Journal of Cancer*, vol. 136, no. 5, pp. E359–E386, 2015.
- [4] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: a Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.
- [5] H. Sung, J. Ferlay, R. L. Siegel et al., "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: a Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.
- [6] W. Sun and L. Yan, "Gastric cancer: current and evolving treatment landscape," *Chinese Journal of Cancer*, vol. 35, no. 1, p. 83, 2016.
- [7] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2018," *CA: a Cancer Journal for Clinicians*, vol. 68, no. 1, pp. 7–30, 2018.
- [8] I. V. Kurochkin, N. Yonemitsu, S. I. Funahashi, and H. Nomura, "ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas," *Biochemical and Biophysical Research Communications*, vol. 280, no. 1, pp. 340–347, 2001.
- [9] R. Cartoni, M. W. Norsworthy, F. Bei et al., "The mammalian-specific protein *Armcx1* regulates mitochondrial transport during axon regeneration," *Neuron*, vol. 92, no. 6, pp. 1294–1307, 2016.
- [10] L. Pang, J. F. Li, L. Su et al., "ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via the PAR-1/rho GTPase signaling pathway," *Journal of Gastroenterology*, vol. 53, no. 1, pp. 71–83, 2018.
- [11] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, no. W1, pp. W98–W102, 2017.
- [12] T. Li, J. Fan, B. Wang et al., "TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells," *Cancer Research*, vol. 77, no. 21, pp. e108–e110, 2017.
- [13] M. E. Ritchie, B. Phipson, D. Wu et al., "Limma powers differential expression analyses for RNA-sequencing and microarray studies," *Nucleic Acids Research*, vol. 43, no. 7, article e47, 2015.
- [14] F. Pontén, K. Jirstrom, and M. Uhlen, "The human protein atlas—a tool for pathology," *The Journal of Pathology*, vol. 216, no. 4, pp. 387–393, 2008.
- [15] M. Uhlén, L. Fagerberg, B. M. Hallström et al., "Proteomics. Tissue-based map of the human proteome," *Science*, vol. 347, no. 6220, p. 1260419, 2015.
- [16] A. Subramanian, P. Tamayo, V. K. Mootha et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 43, pp. 15545–15550, 2005.

- [17] T. Wang, H. Zhong, Y. Qin et al., "ARMCX family gene expression analysis and potential prognostic biomarkers for prediction of clinical outcome in patients with gastric carcinoma," *BioMed Research International*, vol. 2020, Article ID 3575038, 16 pages, 2020.
- [18] F. Zeng, K. Liao, J. Wu et al., "ALEX1 may be a novel biomarker for human cervical squamous cell carcinoma," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 8, pp. 9434–9439, 2015.
- [19] Y. Li, X. Wei, Q. Wang, W. Li, and T. Yang, "Inverse screening of simvastatin kinase targets from glioblastoma druggable kinome," *Computational Biology and Chemistry*, vol. 86, p. 107243, 2020.
- [20] L. Wang, Y. Zhou, L. Jiang et al., "CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway," *Molecular Cancer*, vol. 20, no. 1, p. 43, 2021.
- [21] V. Ecker, M. Stumpf, L. Brandmeier et al., "Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia," *Nature Communications*, vol. 12, no. 1, p. 3526, 2021.
- [22] A. Rambur, C. Lours-Calet, C. Beaudoin et al., "Sequential Ras/MAPK and PI3K/AKT/mTOR pathways recruitment drives basal extrusion in the prostate-like gland of *Drosophila*," *Nature Communications*, vol. 11, no. 1, p. 2300, 2020.
- [23] J. Polivka Jr. and F. Janku, "Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway," *Pharmacology & Therapeutics*, vol. 142, no. 2, pp. 164–175, 2014.
- [24] R. Lu, Z. Yang, G. Xu, and S. Yu, "miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer," *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, vol. 105, pp. 633–644, 2018.
- [25] Q. Wang, J. Mo, C. Zhao et al., "Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells," *Cell Death & Disease*, vol. 9, no. 3, p. 376, 2018.
- [26] E. K. Lam, X. Wang, V. Y. Shin et al., "A microRNA contribution to aberrant Ras activation in gastric cancer," *American Journal of Translational Research*, vol. 3, no. 2, pp. 209–218, 2011.
- [27] T. Matsuoaka and M. Yashiro, "The role of PI3K/Akt/mTOR signaling in gastric carcinoma," *Cancers*, vol. 6, no. 3, pp. 1441–1463, 2014.
- [28] H. Li, Z. Zhang, L. Chen et al., "Cytoplasmic Asporin promotes cell migration by regulating TGF- β /Smad2/3 pathway and indicates a poor prognosis in colorectal cancer," *Cell Death & Disease*, vol. 10, no. 2, p. 109, 2019.
- [29] S. Fulda, "Modulation of mitochondrial apoptosis by PI3K inhibitors," *Mitochondrion*, vol. 13, no. 3, pp. 195–198, 2013.
- [30] G. Di Benedetto, A. Gerbino, and K. Lefkimmatis, "Shaping mitochondrial dynamics: the role of cAMP signalling," *Biochemical and Biophysical Research Communications*, vol. 500, no. 1, pp. 65–74, 2018.
- [31] R. M. Denton, "Regulation of mitochondrial dehydrogenases by calcium ions," *Biochimica et Biophysica Acta*, vol. 1787, no. 11, pp. 1309–1316, 2009.
- [32] J. J. Wen, C. B. Cummins, and R. S. Radhakrishnan, "Burn-induced cardiac mitochondrial dysfunction via interruption of the PDE5A-cGMP-PKG pathway," *International Journal of Molecular Sciences*, vol. 21, no. 7, p. 2350, 2020.
- [33] Q. Ding, M. Zhang, and C. Liu, "Asporin participates in gastric cancer cell growth and migration by influencing EGF receptor signaling," *Oncology Reports*, vol. 33, no. 4, pp. 1783–1790, 2015.
- [34] D. Simkova, G. Kharaishvili, G. Korinkova et al., "The dual role of asporin in breast cancer progression," *Oncotarget*, vol. 7, no. 32, pp. 52045–52060, 2016.
- [35] Y. Ou, X. Zheng, Y. Gao et al., "Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics," *Urologic Oncology*, vol. 32, no. 1, pp. 47.e21–47.e28, 2014.
- [36] D. Xian and Y. Zhao, "lncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signalling pathway," *Journal of Cellular and Molecular Medicine*, vol. 23, no. 6, pp. 3808–3823, 2019.
- [37] S. Hassan, Y. Karpova, A. Flores et al., "A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies," *International Urology and Nephrology*, vol. 46, no. 3, pp. 505–510, 2014.
- [38] D. Trigo, M. B. Goncalves, and J. Corcoran, "The regulation of mitochondrial dynamics in neurite outgrowth by retinoic acid receptor β signaling," *FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology*, vol. 33, no. 6, pp. 7225–7235, 2019.
- [39] Y. R. Zheng, X. N. Zhang, and Z. Chen, "Mitochondrial transport serves as a mitochondrial quality control strategy in axons: implications for central nervous system disorders," *CNS Neuroscience & Therapeutics*, vol. 25, no. 7, pp. 876–886, 2019.
- [40] K. M. Debatin, D. Poncet, and G. Kroemer, "Chemotherapy: targeting the mitochondrial cell death pathway," *Oncogene*, vol. 21, no. 57, pp. 8786–8803, 2002.
- [41] E. Bahar, S. Y. Han, J. Y. Kim, and H. Yoon, "Chemotherapy resistance: role of mitochondrial and autophagic components," *Cancers*, vol. 14, no. 6, p. 1462, 2022.
- [42] M. Kumazoe, K. Sugihara, S. Tsukamoto et al., "67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis," *The Journal of Clinical Investigation*, vol. 123, no. 2, pp. 787–799, 2013.
- [43] G. R. Monteith, D. McAndrew, H. M. Faddy, and S. J. Roberts-Thomson, "Calcium and cancer: targeting Ca^{2+} transport," *Nature Reviews. Cancer*, vol. 7, no. 7, pp. 519–530, 2007.
- [44] A. Bong and G. R. Monteith, "Calcium signaling and the therapeutic targeting of cancer cells," *Biochimica et Biophysica Acta, Molecular Cell Research*, vol. 1865, no. 11 Part B, pp. 1786–1794, 2018.
- [45] G. R. Monteith, F. M. Davis, and S. J. Roberts-Thomson, "Calcium channels and pumps in cancer: changes and consequences," *The Journal of Biological Chemistry*, vol. 287, no. 38, pp. 31666–31673, 2012.
- [46] S. Babykutty, P. Suboj, P. Srinivas, A. S. Nair, K. Chandramohan, and S. Gopala, "Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways," *Clinical & Experimental Metastasis*, vol. 29, no. 5, pp. 471–492, 2012.
- [47] K. Mujoo, V. G. Sharin, E. Martin et al., "Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation," *Nitric Oxide : Biology and Chemistry*, vol. 22, no. 1, pp. 43–50, 2010.

- [48] D. D. Browning, I. K. Kwon, and R. Wang, "cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment," *Future Medicinal Chemistry*, vol. 2, no. 1, pp. 65–80, 2010.
- [49] R. E. Perri, D. A. Langer, S. Chatterjee et al., "Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation," *Gastrointestinal and Liver Physiology*, vol. 290, no. 3, pp. G535–G542, 2006.
- [50] M. Yang, Q. Huang, C. Li et al., "TOX acts as a tumor suppressor by inhibiting mTOR signaling in colorectal cancer," *Frontiers in Immunology*, vol. 12, p. 647540, 2021.
- [51] A. Cerwenka, J. L. Baron, and L. L. Lanier, "Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 20, pp. 11521–11526, 2001.
- [52] A. Diefenbach, E. R. Jensen, A. M. Jamieson, and D. H. Raulet, "Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity," *Nature*, vol. 413, no. 6852, pp. 165–171, 2001.
- [53] J. Galon, A. Costes, F. Sanchez-Cabo et al., "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome," *Science*, vol. 313, no. 5795, pp. 1960–1964, 2006.